QT Imaging Announces Presentation at SPIE Medical Imaging 2026
MWN-AI** Summary
QT Imaging Holdings, Inc. (NASDAQ: QTI), a medical device innovator focused on breast health management with radiation-free imaging technology, announced that its Chief Science Officer, Bilal Malik, Ph.D., will present at the SPIE Medical Imaging 2026 conference in Vancouver, BC, from February 15-19, 2026. This esteemed event, celebrating its 50th anniversary, gathers global experts to discuss advancements in medical imaging, including artificial intelligence (AI) and ultrasound innovations.
Dr. Malik's presentation, titled “Automated breast boundary extraction from reflection data in breast acoustic CT,” will showcase QT Imaging's pioneering method for precisely defining breast boundaries in Breast Acoustic CT™ scans. Accurate boundary detection is essential for enhancing image formation and analysis, thus contributing to improved clinical utility. Dr. Malik elaborated on the significance of their multi-step algorithm that identifies primary reflection events in the scans, filters and interpolates data, and compensates for missing information near the chest wall. This approach, designed for speed and validated with extensive datasets, emphasizes the technology's maturity and integration into QT Imaging's software systems.
The advancements outlined in Dr. Malik's presentation not only enhance breast boundary detection but also lay the groundwork for QT Imaging’s future initiatives in AI and machine learning. These include automated lesion segmentation and clinical decision support tools, aiming to streamline clinical workflows and provide actionable insights from imaging scans.
As a publicly traded company, QT Imaging remains committed to improving global health outcomes through its innovative imaging technologies. Further information about their initiatives and products can be found on the company’s website.
MWN-AI** Analysis
QT Imaging Holdings, Inc. (NASDAQ: QTI) has positioned itself as a pioneering player in the medical imaging sector, particularly with breast health technology. Their recent announcement regarding the presentation by Chief Science Officer Dr. Bilal Malik at the SPIE Medical Imaging conference highlights strategic advancements in their imaging technology, particularly the Breast Acoustic CT™ system.
Investors should take note of this development for several reasons. First, the focus on automated breast boundary extraction can significantly enhance the accuracy of imaging diagnostics. This is crucial in a healthcare landscape where precision and speed are paramount, especially in breast cancer detection.
Second, QT Imaging’s integration of AI and machine learning into its imaging process is a strong market differentiator. The multi-step algorithm that Dr. Malik will discuss not only refines the imaging process but also positions QT Imaging at the forefront of combining advanced technology with practical clinical application. This can lead to stronger clinical partnerships and enhance the company's credibility in the medical community.
Moreover, the ongoing research and planned AI/ML initiatives could open new revenue streams for QT Imaging through automated lesion segmentation and clinical decision support tools. As healthcare increasingly pivots to technology-driven solutions, companies that can innovate in this space may see enhanced investor interest and market performance.
However, potential investors should remain aware of the risks highlighted in the company's forward-looking statements. The path to commercialization is often fraught with challenges, including regulatory hurdles and market acceptance of new technologies.
In conclusion, QT Imaging’s presentation at the SPIE Medical Imaging Conference serves as a catalyst for potential growth opportunities. Long-term investors should monitor these developments closely while being cognizant of the inherent risks associated with the medical device industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
QT Imaging Holdings, Inc. (NASDAQ: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce that its Chief Science Officer, Bilal Malik, Ph.D., will present at the prestigious International Society for Optics & Photonics (“SPIE”) Medical Imaging meeting taking place in Vancouver, BC, Canada, from February 15–19, 2026.
SPIE Medical Imaging 2026 is a premier international symposium focusing on the latest research in medical image processing, physics, and computer-aided diagnosis. The event, which is in its 50th year, covers advancements in AI, ultrasound, digital pathology, and image-guided procedures.
In his oral presentation, titled “Automated breast boundary extraction from reflection data in breast acoustic CT,” Dr. Malik will highlight an automated method to accurately define the breast boundary in QT Imaging Breast Acoustic CT™ scans, a critical step in image formation and analysis. The work reflects QT Imaging’s broader strategy to combine advanced physics-based imaging with modern artificial intelligence and machine learning (AI/ML) tools to enhance clinical utility.
“Accurate breast boundary detection guides the nonlinear optimization for image reconstructions, determines the gain factor for reflection imaging, enables water-region denoising, supports calculation of breast density, and enhances the robustness of QT Imaging’s reconstruction pipeline,” said Dr. Malik.
“We developed a multi-step algorithm that extracts the breast boundary from reflection data by detecting primary reflection events, refining them through filtering and interpolation, and compensating for missing data near the chest wall via extrapolation. This algorithm is fast, validated on a large dataset, and fully integrated into QT Imaging’s production software, underscoring the maturity of the technology.”
This work also serves as a foundation for QT Imaging’s planned AI/ML initiatives, including automated lesion segmentation and clinical decision support tools. By pairing precise boundary detection with advanced machine learning, the Company aims to improve lesion characterization, streamline clinical workflows, and provide clinicians with more actionable insights from each scan.
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com .
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the upcoming presentation and the planned AI/ML initiatives, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QTI Breast Acoustic CT scanner, clinical studies, the ability of QT Imaging to sell and deploy the QTI Breast Acoustic CT scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260203862234/en/
For media inquiries, please contact:
Stephen Kilmer
Head of Investor Relations
Stephen.Kilmer@qtimaging.com
Direct: (646) 274-3580
FAQ**
How does QT Imaging Holdings Inc Com QTI plan to leverage AI/ML initiatives to improve clinical workflows and lesion characterization in breast imaging?
What are the expected commercial applications for the automated breast boundary extraction technology developed by QT Imaging Holdings Inc Com QTI?
Can you explain the validation process of the multi-step algorithm used for breast boundary detection in QT Imaging Holdings Inc Com QTI’s Breast Acoustic CT scans?
What specific risks and uncertainties should investors consider related to the upcoming product developments and market introduction of QT Imaging Holdings Inc Com QTI's technology?
**MWN-AI FAQ is based on asking OpenAI questions about QT Imaging Holdings Inc Com (NASDAQ: QTI).
NASDAQ: QTI
QTI Trading
1.09% G/L:
$6.005 Last:
37,927 Volume:
$6 Open:
